Abbott Laboratories stock (NYSE: ABT) has increased 11.3% in the past 12 months.Since the beginning of 2025, the share price has continued to increase by 13.56%. making ABT a slight underperformer on the NYSE index, up 14.2% over the same period.
However, Abbott has not been immune to challenges. The most significant setback in the past year has been the legal verdict in July 2024, where a St. Louis jury found Abbott’s premature infant baby formula responsible for a potentially fatal bowel disease.
The $495 million verdict against the company sent shockwaves through the market, leading to a notable decline in ABT stock. This legal outcome exposed vulnerabilities in Abbott’s nutritional products division and raised concerns about potential future liabilities. The verdict serves as a stark reminder of the risks associated with product liability and the importance of rigorous quality control.
Abbott Laboratories Share Price Targets
Analysts have set a 12-month price target for Abbott Laboratories with an average expectation of $141.12, ranging from a high of $159.00 to a low of $120.12.
Our View: You would be wise to consider the views of the analyst community in conjunction with the fundamentals surrounding the company to properly determine a value for the stock that you feel is appropriate.
At the upper end of analysts estimates it would be easy to get carried away with the potential gains on show, but the flipside is that these targets can shift within the blink of an eye and that the view of analysts is very dynamic.
If you are considering swing trading, or day trading Abbott Laboratories shares that is a separate consideration, but for those planning for the long haul, fundamental analysis is king.
Abbott Laboratories – The Basics Driving The Business
Abbott is a diversified healthcare powerhouse. Its medical devices segment, which includes cardiovascular devices like stents and pacemakers, as well as neuromodulation and diabetes care products, has been a significant growth driver.
The diagnostics division, offering a wide array of testing solutions for infectious diseases, cardiac markers, and other health conditions, has proven particularly vital in a world still navigating evolving healthcare needs.
The nutritional products segment, encompassing infant formulas and adult nutritionals, provides a steady, albeit recently challenged, revenue stream.
Finally, Abbott’s established pharmaceuticals division focuses on branded generic drugs in emerging markets. This diversification has historically provided a buffer against sector-specific downturns, but recent events have tested this resilience.
The past year has been a period of both triumph and tribulation for Abbott. On the innovation front, the company has made significant strides. The CE Mark approval in Europe for its Volt™ Pulsed Field Ablation (PFA) System is a major win.
This system, designed to treat atrial fibrillation (AFib), boasts an impressive 99.1% success rate in pulmonary vein isolation during clinical trials, which suggests that they will have a huge advantage over pre-existing treatments and therapies.
The approval allows Abbott to begin commercial cases in the EU, potentially capturing a significant share of the growing market for AFib treatments. This represents a considerable opportunity for revenue growth and reinforces Abbott’s position as a leader in cardiovascular technology.
Further bolstering its cardiovascular portfolio, Abbott has received FDA approval for an investigational device exemption (IDE) to evaluate its Coronary Intravascular Lithotripsy (IVL) System. The TECTONIC trial, enrolling over 300 participants across multiple U.S. sites, will assess the system’s efficacy in treating severe coronary artery calcification.
This initiative highlights Abbott’s ongoing commitment to developing cutting-edge solutions for complex cardiovascular conditions. Success in this trial could pave the way for another significant product launch, further solidifying Abbott’s dominance in the cardiovascular space.
Abbott’s commitment to public health extends beyond its core business operations. The company’s partnership with the Big Ten Conference to launch ‘The We Give Blood Drive’, a nationwide blood donation competition, demonstrates a dedication to addressing critical healthcare needs.
This initiative not only aims to alleviate U.S. blood shortages but also engages younger donors, fostering a culture of giving back. While the direct financial impact of this initiative may be limited, it enhances Abbott’s corporate image and strengthens its ties with communities across the country.
